COLON TARGETED DRUG DELIVERY SYSTEM-AN APPROACH FOR TREATING COLONIC AILMENTS
The colon is a site where both local and systemic delivery of drugs can take place. Local delivery could, for instance, allow topical treatment of inflammatory bowel disease. Treatment could be made more efficient if it was possible for drugs to be targeted like a shot to the colon. Systemic side effects could also be reduced. Colon specific systems might also allow oral administration of peptide and protein drugs, which are normally inactivated in the upper portions of the gastrointestinal tract. Primary approaches for CDDS (Colon Specific Drug Delivery), which includes prodrugs, pH and time dependent systems and microbial triggered drug delivery system achieved limited success and accepting limitations. Newly developed CDDS, which includes pressure controlled colonic delivery capsules (PCDCS), CODESTM and osmotic controlled drug delivery are unparalleled in terms of achieving in vivo site specificity and feasibility of fabrication operation. This review also focuses on evaluations of CDDS in general.
Keywords: Colon specific drug delivery, Prodrugs, CODESTM, PCDCS.
2. Ahrabi SF, Madseh G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacanie. Eur J Pharm Sci 2000;10:43-52.
3. Ahmed S. Effect of simulated gastrointestinal condition on drug release from pectin/ethyl cellulose as film coating for drug delivery to the colon. Drug Dev Ind Pharm 2005;31:465-70.
4. Aiedeh K, Taha MO. Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered colon specific drug delivery system. Arch Pharmacol Res 1999;332:103-7.
5. Akala EO, Elekwachi O, Chase V, Johnson H, Marjorie L, Scott K. Organic redox initiated polymerization process for the fabrication of hydrogel for colon specific drug delivery. Drug Dev Ind Pharm 2003;29:375-86.
6. Ashord M, Fell JT, Attwood D, Sharma H, Woodhead P. An evaluation of pectin as a carrier for drug targeting to the colon. J Controlled Release 1993a;26:213-20.
7. Asford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. Studies on pectin formulations for colonic drug delivery. J Controlled Release 1994;30:225-32.
8. Sinha VR, Rachna K. Coating polymers for colon specific drug delivery: A comparative in vitro evaluation. Acta Pharm 2003;53:41-7.
9. Cavalcanti OA, Mooter GV, Soares IC, Kinget R. Polysaccharides as excipients for colon-specific coatings, permeability and swelling properties of casted films. Drug Dev Ind Pharm 2002;28:157-64.
10. Mehta TJ. Need of colon specific drug delivery system: review on primary and novel approaches. Int J Res Dev 2011;3:134-53.
11. Hita V, Singh R, Jain SK. Colonic targeting of metronidazole using azo aromatic polymers, development and characterization. Drug Delivery 1997;4:19-22.
12. Basit A, Bloor J. Prespectives on colonic drug delivery. Business briefing: Pharmtech; 2003. p. 185-90.
13. Bussemer T, Bodmeier IRO. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2003;18:433-58.
14. Chan RP, Pope DJ, Gilbett AP, Sneta PJ, Baron JH, Bennardjones JF. Studies of two novel sulphasalazine analogs I. P. salazide and balsalazide. Dig Dis Sci 1983;28:609-716.
15. Chavan MS, Sant VP, Nagarsenker MS. Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in vitro evaluation. J Pharm Pharmacol 2001;53:895-900.
16. Jung YJ, Lee JS, Kim HH, Kim YK, Han SK. Synthesis and evaluation of 5-aminosalicylicylglycine as a potential colon specific prodrug of 5-aminosalicylic acid. Arch Pharmacol Res 1998;21:174-8.
17. Vandelli MA, Leo E, Forni F, Bernabei MT. In vitro evaluation of a potential colonic delivery system that releases drug after a controllable lag-time. Eur J Pharm Biopharm 1996;43:148-51.
18. Cole E, Scott R, Connor A, Wilding I, Petereit HU, Schminke C, et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm 2002;231:83-95.
19. Cummings JH, Englyst HN. Fermentation in the human large intestine and available substrates. Am J Clin Nutr 1987;45:1243-55.
20. Cui N, Friend DR, Fedora RN. A budesonide prodrug accelerates of colitis in rats. Gut 1994;35:1439-46.
21. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-92.
22. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-41.
23. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-21.
24. Friend DR, Chang GW. A colon-specific drug delivery system based on drug glycosides and glycosidase of colonic bacteria. J Med Chem 1984;27:261-6.
25. Friend DR, Chang GW. Drug glycosides: potential prodrugs for colon specific drug delivery. J Med Chem 1985;28:51-7.
26. Choudhury PK, Panigrahi TK, Murthy PN, Tripathy NK, Behera S, Panigrahi R. Novel approaches and developments in colon specific drug delivery systems-a review. Web Center Pharm Sci 2012;3:1-20.
27. Philip AK, Philip B. Colon targeted drug delivery system: a review on primary and novel approaches. Oman Med J 2010;25:70-8.
28. Singh KI. Colon specific drug delivery system: review on novel approaches. Int J Pharm Sci Res 2012;3:637-47.
29. Kishore G. Development and evaluation of colon targeted tablets of praziquantel and its Î²-cyclodextrin complex to treat schistosomiasis. J Pharm Sci Technol 2010;2:269-75.
30. Zou MJ, Cheng G, Okamoto H, Hao XH, An F, Cui FD, et al. Colon-specific drug delivery systems based on Cyclodextrin prodrugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J Gastroenterol 2005;11:7457.
31. Friend DR, Phillip S, Tozer TN. Colon specific drug delivery from a glucosidic prodrug in the guinea pig efficacy study. J Controlled Release 1991;15:47-54.
32. Fukui E, Miyamura N, Kobayashi M. An in vitro investigation of the suitability of presscoated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobicn additives in the outer shell for colon targeting. J Controlled Release 2001;70:97-107.
33. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-21.
34. Wakerly Z, Fell J, Attwood D, Parkins D. Studies on amidated pectins as potential carriers in colonic drug delivery. J Pharm Pharmacol 1997;49:622-5.
35. Rubinstin A, Nakar D, Sintov A. Chondroitin sulphate: a potential biodegradable carrier for colon-specific drug delivery. Int J Pharm 1992;84:141-50.
36. Fukui E, Miyamura N, Verma K, Kobayashi M. Preparation of enteric coated time released press coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm 2000;204:7-15.
37. Gazzaniga A, Iamartino P, Maffino G, Sangalli ME. Oral delayed release system for colonic specific drug delivery. Int J Pharm 1994;108:77-83.
38. Hata T, Shimazaki Y, Kagayama A, Tamura S, Ueda S. Development of a novel drug delivery system, time-controlled explosion system (TES). Part 5 Animal pharmacodynamic and human bioavailability studies. Int J Pharm 1994;110:1-7.
39. Hay DJ, Sharma H, Irving MH. Spread of steroid containing foam after intrarectal administration. Br Med J 1979;1:1751-3.
40. Kothawade PD. Conventional and novel approaches for colon specific drug delivery: a review. J Sci Technol 2011;2:33-56.
41. Nanoparticle for colon specific drug delivery system. 3rd International conference on Nanotech and Expo, Las Vegas, USA; 2013.
42. Patel PB, Dhake AS. Multiparticulate approach: an emerging trend in colon specific drug delivery for Chronotherapy. J Pharm Sci 2011;1:59-63.
43. Onuigbo EB, Okore VC, Ngene AA, Esimone CO, Attama AA. Preliminary studies of a stearylamine-based cationic liposome. J Pharm Res 2011;10:25-9.
44. Onuigbo EB, Okore VC, Esimone CO, Ngene A, Attama AA. Preliminary evaluation of the immunoenhancement potential of newcastle disease vaccine formulated as a cationic liposome. Avian Pathol 2012; 41:355-60.
45. Goyal S, Vashist H, Gupta A, Jindal S, Goyal A. Development of alginate gel beads-entrapped liposome for colon specific drug delivery of prednisolone. Pharm Sin 2011;2:31-8.
46. Saffron M, Field JB, Pena J, Jones RH, Ohuda Y. Oral insulin in diabetic dogs. J Endocrinol 1991;131:267-78.
47. Wakerly Z, Fell J, Attwood D, Parkins D. Studies on amidated pectins as potential carriers in colonic drug delivery. J Pharm Pharmacol 1997;49:622-5.
48. Ahrabi SF, Madseh G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacanie. Eur J Pharm Sci 2000;10:43-52.
49. Rubinstin A, Nakar D, Sintov A. Chondroitin sulphate: a potential biodegradable carrier for colon-specific drug delivery. Int J Pharm 1992;84:141-50.
50. Alpsten M, Ekenved G, Soelvell L. A profile scanning method of studying the release properties of different types of tablets in man. Acta Pharm Suec 1976;13:107â€“22.
51. Casey DL, Beihn RM, Digenis GA, Shambu MB. Method for minitoring hard gelatin capsule disintegrationtimes in human using external scintigraphy. J Pharm Sci 1976;65:1412â€“3.
52. Digenis GA, Sandefer E. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit Rev Ther Drug Carrier Syst 1991;7:309â€“45.
53. Wilding IR, Coupe AJ, Davis SS. The role of Î³-scintigraphy in oral drug delivery. Adv Drug Delivery Rev 1991;7:87â€“117.
54. Newman SP, Wilding IR. Imaging techniques for assessing drug delivery in man. Pharm Sci Tech Today 1999;2:269â€“88.
55. Patel A. Novel approaches for colon targeted drug delivery system. J Pharm Cosmetol 2011;1:85-97.